Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris

Trial Profile

An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rilzabrutinib (Primary) ; Prednisone; Rituximab
  • Indications Pemphigus vulgaris
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms Believe-PV
  • Sponsors Principia Biopharma
  • Most Recent Events

    • 03 May 2021 Results (n=27) assessing efficacy and safety of oral rilzabrutinib in patients with pemphigus vulgaris, published in the British Journal of Dermatology.
    • 12 Jun 2020 Results published in the Principia Biopharma Media Release.
    • 12 Jun 2020 According to a Principia Biopharma media release, positive data from the Part B of the study was presented as part of the virtual Late-Breaker session of the American Academy of Dermatology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top